Additionally, we found a positive correlation between SLC5A and both AP1M1 and ARF4, another clathrin-dependent factor involved in NIS trafficking.23 Therefore, AP-1A/B might be a new target to increase NIS trafficking to the PM and improve RAI therapy in patients with refractory thyroid cancer. The gene discussed is AP1M1; the disease is thyroid cancer.